Simris Alg AB Class B (SIMRIS.B) AI Stock Analysis

1 Followers

Simris Alg AB Class B

(Nasdaq OMX AB:SIMRIS.B)

Select Model

Rating:47Neutral

Price Target:SEK 0.10▲(5.26% Upside)

Action:reiterated

Date:10/20/26

The score is held down primarily by very weak financial performance—shrinking revenue, negative gross profit and margins, persistent cash burn, and an extremely leveraged/near-zero equity balance sheet. Technicals provide some offset with moderately positive trend and momentum (price above key moving averages, positive MACD), but valuation remains unfavorable/limited in usefulness due to negative earnings and no dividend data.

Positive Factors

Specialized Algae PlatformA focused microalgae platform gives Simris a defined technological and commercial direction across nutrition and life-science applications. Concentrating on biomass production and extraction of high-value compounds could support product development and create opportunities to build expertise in a specialized niche over time.

Negative Factors

Revenue Contraction and Negative Gross ProfitRevenue contraction combined with negative gross profit shows that the current business is not yet generating sufficient scale or pricing to cover direct costs. Persistent deterioration at the top line and product level weakens operating leverage, limits reinvestment capacity, and leaves profitability recovery dependent on substantial improvement.

Simris Alg AB Class B (SIMRIS.B) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 160.46M
Dividend Yield: ―
Average Volume (3M): 195.42K
Price to Earnings (P/E): -3.3
Beta (1Y): 0.25
Revenue Growth: -50.41%
EPS Growth: 56.74%
Country: Sweden
Employees: 5
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Simris Alg AB Class B Business Overview & Revenue Model

Company Description

Operating both within Sweden and across global markets, Simris Alg AB (publ) specializes in the production and sale of nutritional supplements and food products derived from algae. Its product portfolio includes Simris Algae Omega-3, a unique plant-d...

Simris Alg AB Class B Financial Statement Overview

Summary

Financials indicate severe stress: revenue is down materially (TTM -26.1%) after multi-year declines, gross profit is negative (products/services not covering direct costs), and margins remain deeply negative. The balance sheet is a major risk with near-zero equity (TTM ~SEK 0.8m) against high debt (~SEK 89.7m), implying extreme leverage and refinancing/dilution risk. Cash flow is also weak with ongoing cash burn (TTM operating cash flow -SEK 15.4m; free cash flow -SEK 12.8m), keeping the company dependent on external funding.

Income Statement

12Very Negative

Balance Sheet

8Very Negative

Cash Flow

18Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.39M	1.61M	2.89M	4.35M	4.08M	6.14M
Gross Profit	-21.63M	-31.34M	1.22M	2.01M	-742.00K	-2.07M
EBITDA	-15.43M	-17.32M	-19.79M	-22.36M	-18.00M	-24.81M
Net Income	-25.63M	-26.81M	-34.60M	-37.30M	-24.42M	-28.36M
Balance Sheet
Total Assets	137.73M	148.38M	157.06M	174.55M	185.71M	29.20M
Cash, Cash Equivalents and Short-Term Investments	7.99M	1.47M	1.95M	5.67M	3.99M	961.00K
Total Debt	89.69M	87.68M	2.04M	2.67M	2.13M	3.13M
Total Liabilities	136.97M	148.85M	151.42M	148.94M	162.68M	10.98M
Stockholders Equity	767.00K	-470.00K	5.64M	25.61M	23.03M	18.22M
Cash Flow
Free Cash Flow	-12.83M	-16.27M	-18.63M	-37.96M	-40.57M	-18.39M
Operating Cash Flow	-15.38M	-16.05M	-18.02M	-36.35M	-18.19M	-18.14M
Investing Cash Flow	-552.00K	-224.00K	-613.00K	-1.61M	-22.38M	-253.00K
Financing Cash Flow	22.89M	15.79M	14.91M	39.63M	43.60M	2.84M

Simris Alg AB Class B Technical Analysis

Technical Analysis SentimentNegative

Last Price0.10

Price Trends

50DMA0.11Negative

100DMA0.11Negative

200DMA0.10Negative

Market Momentum

MACD-0.00Positive

RSI36.44Neutral

STOCH18.91Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SIMRIS.B, the sentiment is Negative. The current price of 0.10 is below the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.11, and below the 200-day MA of 0.10, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 36.44 is Neutral, neither overbought nor oversold. The STOCH value of 18.91 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SIMRIS.B.

Simris Alg AB Class B Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SE:SIMRIS.B against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:SIMRIS.B	47Neutral	SEK 160.46M	-3.35	1209.72%	―	-50.41%	56.74%
SE:BIOEX	42Neutral	SEK 113.54M	-5.57	-116.56%	―	-37.50%	1.01%
SE:MAGLE	41Neutral	SEK 63.60M	-0.03	-46.30%	―	1.80%	-1367.42%
SE:IBT.B	39Underperform	SEK 961.86M	-11.44	-89.70%	―	―	19.94%

* Healthcare Sector Average

Performance Comparison

SE:SIMRIS.B and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:SIMRIS.B	Simris Alg AB Class B	0.10	-0.01	-12.84%
SE:IBT.B	Infant Bacterial Therapeutics	69.70	17.70	34.04%
SE:MAGLE	Magle Chemoswed Holding AB	0.25	-20.55	-98.78%
SE:BIOEX	Bioextrax AB	2.42	0.38	18.80%
SE:BIOWKS	Bio-Works Technologies AB	3.02	0.27	9.82%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 20, 2026

Simris Alg AB Class B AI Stock Analysis